Press Releases

Kabul, Afghanistan – The United States congratulates Afghanistan on the successful arrival of 468,000 doses of the COVISHIELD vaccine, from the AstraZeneca Serum Institute, on March 8, 2021.  This shipment was made possible through the COVAX Advance Market Commitment, a global initiative to support equitable access to COVID-19 vaccines.  The United States recently announced the provision of an initial $2 billion—out of a total planned $4 billion—to the COVAX Advance Market Commitment, making the United States the single largest contributor to COVAX.  Afghanistan is among the first countries in the region to have received COVID-19 vaccines through the COVAX facility.

“The United States stands with Afghanistan in its fight against COVID-19, which poses an unprecedented global health threat,” said U.S. Charge d’Affaires Ian McCary. “Defeating the pandemic is a global challenge and the United States is working both at home and abroad to stop the spread of the disease.  Working together, we can defeat COVID-19 and prepare ourselves for future threats.”